AstraZeneca PLC News
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
see moreAstraZeneca PLC Market News
3d
AstraZeneca's Bold Move: Fusion Buy & Nasdaq Exit.
- AstraZeneca accelerated its oncology strategy this week by agreeing to acquire Fusion Pharmaceuticals for about $2.4B while concurrently being removed from the NASDAQ‑100. Strong Q4 2025 results and reiterated long‑term targets frame the deal as a pipeline‑strengthening move with measurable implications for investors.
19 Feb at 00:38
AstraZeneca Exits Nasdaq-100; Lists on NYSE US Now
AstraZeneca (AZN) completed a U.S. listing shift this week, moving ordinary shares to the NYSE and exiting the Nasdaq‑100. The change—paired with multi‑billion dollar investments in the U.S. and China and a strategic CSPC collaboration—has immediate index and liquidity effects and strengthens AstraZeneca's metabolic/obesity pipeline.
05 Feb at 00:37
AstraZeneca Surges, Exits Nasdaq-100; Pipeline Win
AstraZeneca (AZN) hit an all-time high in early February even after formal removal from the Nasdaq‑100 in mid‑January. Recent regulatory progress for Imfinzi, a major collaboration with China's CSPC in obesity and diabetes, and a harmonized NYSE listing underpin the stock’s momentum while the Nasdaq‑100 exit may trim passive inflows.
29 Jan at 00:37
AZN Exits Nasdaq-100; NYSE Listing & AI Deal Alert
AstraZeneca (AZN) was removed from the Nasdaq‑100 on Jan 20, 2026, is shifting its U.S. listing to the NYSE in early February, and has acquired Modella AI to speed oncology R&D—moves that change index-driven flows, trading composition, and long-term strategy.
22 Jan at 00:37
AstraZeneca Loses Nasdaq-100 Spot; What's Next
AstraZeneca's switch from Nasdaq ADSs to NYSE ordinary shares and its removal from the Nasdaq‑100 triggered heavy trading and a sharp share drop. This article explains the mechanics of the transition, immediate index-driven flows, near-term risks ahead of February earnings, and longer-term strategic implications for AZN investors.
15 Jan at 00:38
AstraZeneca Nasdaq Exit and ENHERTU FDA Decisions
AstraZeneca faces removal from the Nasdaq-100 on Jan 20, 2026, days before a critical FDA decision (Jan 23, 2026) on an ENHERTU + pertuzumab first-line indication for HER2‑positive metastatic breast cancer. The near-term index-driven outflows could pressure AZN shares, while a favorable FDA outcome would be a meaningful commercial and sentiment catalyst.
08 Jan at 00:36
AstraZeneca: Onshoring Gains, Pricing Risks 2026.
Recent coverage shows AstraZeneca (AZN) benefiting from U.S. onshoring and strong oncology sales while facing pricing scrutiny in Europe. Key operational moves and discrete regulatory wins propelled sentiment this week, even as semaglutide pricing and policy risk temper the outlook.